Dr. Meyer emphasized that the type of blockages his team studied are rare, and all the centers involved in this study were tertiary stroke centers with a high level of expertise in these kinds of interventions.
Selection of patients for thrombectomy remains a key issue, Dr. Meyer said, especially when patients are not eligible for randomization in a designated trial.
Ad Statistics
Times Displayed: 45175
Times Visited: 1385 Keep biomedical devices ready to go, so care teams can be ready to care for patients. GE HealthCare’s ReadySee™ helps overcome frustrations due to lack of network and device visibility, manual troubleshooting, and downtime.
“As we anticipate an increasing number of patients with medium vessel occlusions being treated with thrombectomy, age and eloquence of symptoms in particular are factors that should be considered when making treatment decisions,” he said. “Ultimately, the results of ongoing randomized trials will provide further insight into this subgroup.”
Dr. Meyer plans to conduct further analysis of a subgroup of these patients to gain a deeper understanding of procedural and clinical outcomes. He also wants to identify potential surrogate markers that can predict clinical course.
“By focusing on this specific patient population, we hope to further advance our knowledge and improve patient outcomes,” he said.
Back to HCB News
